Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Cut to $320.00 by Analysts at Oppenheimer

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target reduced by Oppenheimer from $350.00 to $320.00 in a research note issued to investors on Friday. They currently have an outperform rating on the biopharmaceutical company’s stock.

ALNY has been the subject of a number of other research reports. Royal Bank Of Canada cut their price objective on shares of Alnylam Pharmaceuticals from $345.00 to $280.00 and set an “outperform” rating for the company in a report on Friday. UBS Group reissued a “buy” rating and issued a $329.00 target price (down from $550.00) on shares of Alnylam Pharmaceuticals in a research note on Friday. Wall Street Zen cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 2nd. Morgan Stanley dropped their price target on Alnylam Pharmaceuticals from $300.00 to $240.00 and set an “equal weight” rating for the company in a research report on Friday. Finally, Truist Financial cut their price target on Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating for the company in a report on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $317.95.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $165.00 on Friday. Alnylam Pharmaceuticals has a 52-week low of $163.30 and a 52-week high of $479.79. The firm has a market capitalization of $22.08 billion, a price-to-earnings ratio of 8.57 and a beta of 0.28. The company has a fifty day simple moving average of $236.49 and a 200-day simple moving average of $286.19. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 EPS for the quarter, beating analysts’ consensus estimates of $1.66 by $14.60. The business had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.43 billion. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 246.94%. The company’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period in the prior year, the business earned $2.90 earnings per share. On average, equities analysts anticipate that Alnylam Pharmaceuticals will post 6.43 EPS for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Bryan Supran sold 1,758 shares of the company’s stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the sale, the executive vice president owned 12,807 shares of the company’s stock, valued at approximately $2,905,652.16. This represents a 12.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.86% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the company. SCS Capital Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $34,784,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth approximately $50,773,000. Silvant Capital Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth approximately $5,456,000. WINTON GROUP Ltd acquired a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth approximately $2,372,000. Finally, Wealthfront Advisers LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at approximately $2,876,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

More Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Quarterly results exceeded expectations. Alnylam reported $16.26 in adjusted earnings per share versus the $1.66 consensus estimate, while revenue rose 16.7% year over year to $1.46 billion, slightly above forecasts. The company maintained its fiscal 2026 product-sales outlook and expects $4.2 billion–$4.5 billion in 2026 TTR sales. Alnylam Q3 earnings beat
• Positive Sentiment: Several analysts still see substantial long-term upside. Chardan Capital, TD Cowen, Goldman Sachs and RBC retained positive ratings, although they reduced their price targets. Their revised targets remain well above the current trading level. Chardan Capital rating
• Neutral Sentiment: Pipeline investment could support future growth but increases execution risk. Alnylam expanded the TRITON-CM nucresiran heart-disease study to approximately 2,250 patients while maintaining an anticipated launch around 2030. Management described its conviction in the program as high, but the longer timeline limits near-term revenue benefits. Alnylam TTR sales and trial update
• Negative Sentiment: Demand-growth concerns overshadowed the earnings beat. Slower Amvuttra patient starts and moderating U.S. Amvuttra and Onpattro sales growth raised concerns that the company’s core TTR business may be losing momentum. Management also acknowledged that it needs to improve execution, adding to uncertainty around the franchise. ALNY demand growth concerns
• Negative Sentiment: Analyst sentiment became more cautious. Bernstein downgraded ALNY to “market perform,” while Stifel cut its rating to “hold.” Multiple firms lowered price targets, including Bernstein from $376 to $199 and Goldman Sachs from $536 to $320, reflecting increased valuation and policy risks.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.